Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Amortizatization of Intangibles: 2020-2025

Historic Amortizatization of Intangibles for Tango Therapeutics (TNGX) over the last 5 years, with Sep 2025 value amounting to $973,000.

  • Tango Therapeutics' Amortizatization of Intangibles rose 182.04% to $973,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.1 million, marking a year-over-year increase of 175.41%. This contributed to the annual value of -$4.6 million for FY2024, which is 228.04% down from last year.
  • Per Tango Therapeutics' latest filing, its Amortizatization of Intangibles stood at $973,000 for Q3 2025, which was down 4.42% from $1.0 million recorded in Q2 2025.
  • In the past 5 years, Tango Therapeutics' Amortizatization of Intangibles registered a high of $2.7 million during Q2 2023, and its lowest value of -$1.4 million during Q1 2024.
  • Its 3-year average for Amortizatization of Intangibles is $181,091, with a median of $911,000 in 2023.
  • Over the last 5 years, Tango Therapeutics' Amortizatization of Intangibles had its largest YoY gain of 614.97% in 2023, and its largest YoY loss of 347.37% in 2023.
  • Tango Therapeutics' Amortizatization of Intangibles (Quarterly) stood at $321,000 in 2021, then spiked by 174.77% to $882,000 in 2022, then climbed by 3.63% to $914,000 in 2023, then plummeted by 193.65% to -$856,000 in 2024, then spiked by 182.04% to $973,000 in 2025.
  • Its Amortizatization of Intangibles stands at $973,000 for Q3 2025, versus $1.0 million for Q2 2025 and $1.0 million for Q1 2025.